» Articles » PMID: 39701036

Emerging Approaches for T cell-stimulating Platform Development

Overview
Journal Cell Syst
Publisher Cell Press
Date 2024 Dec 19
PMID 39701036
Authors
Affiliations
Soon will be listed here.
Abstract

T cells are key mediators of the adaptive immune response, playing both direct and supporting roles in the destruction of foreign pathogenic threats as well as pathologically transformed host cells. The natural process through which T cells are activated requires coordinated molecular interactions between antigen-presenting cells and T cells. Promising advances in biomaterial design have catalyzed the development of artificial platforms that mimic the natural process of T cell stimulation, both to bolster the performance of cell therapies by activating T cells ex vivo prior to adoptive cell transfer and to directly activate T cells in vivo as off-the-shelf treatments. This review focuses on innovative strategies in T cell-stimulating platform design for applications in cancer therapy. We specifically highlight progress in bead-based artificial antigen-presenting cell engineering, hydrogel-based scaffolds, DNA-based systems, alternative polymeric strategies, and soluble activation approaches. Collectively, these advances are expanding the repertoire of tools for targeted immune activation.

References
1.
Voss S, Skerra A . Mutagenesis of a flexible loop in streptavidin leads to higher affinity for the Strep-tag II peptide and improved performance in recombinant protein purification. Protein Eng. 1997; 10(8):975-82. DOI: 10.1093/protein/10.8.975. View

2.
Shah K, Al-Haidari A, Sun J, Kazi J . T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther. 2021; 6(1):412. PMC: 8666445. DOI: 10.1038/s41392-021-00823-w. View

3.
Iwai Y, Terawaki S, Honjo T . PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2004; 17(2):133-44. DOI: 10.1093/intimm/dxh194. View

4.
Perica K, Bieler J, Schutz C, Varela J, Douglass J, Skora A . Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy. ACS Nano. 2015; 9(7):6861-71. PMC: 5082131. DOI: 10.1021/acsnano.5b02829. View

5.
Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton J, Curbishley S . Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021; 124(11):1759-1776. PMC: 8144577. DOI: 10.1038/s41416-021-01353-6. View